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Abstract: The myriad pain pathophysiology has intrigued and challenged humanity for 
centuries. In this regard, the traditional pain therapies such as opioids and nonsteroidal anti-
inflammatory drugs have been highly successful in treating acute and chronic pain. However, 
their drawback includes adverse events such as psychotropic effects, addiction potential, and 
gastrointestinal toxicities, to mention a few. These factors combined with the likelihood of an 
increase in chronic pain conditions due to an aging population calls for the development of 
novel mechanism-based or “site-specific” agents to target novel pain pathways. In this regard, 
rapid progress has been made in understanding the molecular mechanisms of novel pain tar-
gets such as cannabinoid receptors, fatty acid hydrolase, voltage-gated and ligand-gated ion 
channels such as P2 receptors, transient receptor potential channels and glial cell modulators. 
Accordingly, preclinical studies indicate that the site-specific/selective agents exhibit sufficient 
efficacy and reduced side effects such as lack of psychotropic effects indicating their clinical 
potential. This review provides a brief summary of some “at-site” pain targets and their role 
in the pain pathophysiology, and describes the efforts in developing some small molecules as 
novel pain therapeutics.
Keywords: opioids, nonsteroidal anti-inflammatory drugs, cannabinoid receptors, P2X receptors, 
transient receptor potential channels, glial cells
Introduction
The word “pain” is simple, yet complex. The quest of humans to conquer pain by 
investigating the underlying cause is a challenging and ongoing process. According 
to the International Association for the Study of Pain, the definition of pain as “an 
unpleasant sensory and emotional experience associated with actual or potential   tissue 
damage, or described in terms of such damage” indicates the subjective nature of pain.1 
It is the most common complaint for which patients seek medical attention, lose pro-
ductivity, and incur health care costs.2 The epidemic status of pain across the globe is 
highlighted by a recent study which showed that nearly 37.3% and 41.1% of the adult 
population in the developed and developing countries, respectively, experience chronic 
pain due to diseases or disorders or injuries.3 Pain is characterized by both physical 
and psychological symptoms. Based on clinical characteristics, pain can be classified 
as nociceptive, neuropathic, or psychogenic/idiopathic.2,4–6 The mechanical, chemical, 
or thermal stimulation of peripheral sensory nerves due to surgery or trauma in a well 
localized area is described as nociceptive pain, whereas neuropathic pain is defined as 
an abnormal signaling resulting from injury or dysfunction of the peripheral or central 
nervous system (CNS) leading to pain. In addition, the latter is less localized and can Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
280
Rao and Mohamed
persist in the absence of visible injury or inflammation.7–11 
Pain perception/assessment in patients with personality 
disorders, mood disorders, or substance abuse indicates the 
influence of psychiatric disorders on pain etiology.12,13 Tradi-
tional pain-management therapies involve analgesics such as 
acetaminophen and aspirin, nonsteroidal anti-inflammatory 
drugs (NSAIDs) such as ibuprofen and indomethacin, and 
narcotics such as morphine.14,15 However, there is a growing 
concern on the risks of overdose, abuse, and addiction poten-
tial of these agents. For example, in the United States alone, 
about 30,000 hospitalizations are   attributed to acetamino-
phen overdose, whereas NSAID therapy is associated with 
fatal gastrointestinal bleeding and potential cardiovascular 
risks.16–18 In addition, narcotic analgesic abuse and addiction 
is a serious concern.19 These facts mandate the need to look 
beyond traditional pain targets such as cyclooxygenases and 
opioid receptors. The complexity in understanding the pain 
mechanisms listed in   Figure 1 will go a long way in devel-
oping new therapies.   Current research efforts are ongoing 
to discover agents with superior efficacy and safety profiles 
that target novel   pathological routes as pain therapeutics 
(Figure 1). Emerging pain targets include cannabinoid (CB) 
receptors, fatty acid amide   hydrolase (FAAH), voltage- and 
ligand-gated ion channels (sodium   channels, T-type calcium 
channels, N-type calcium channels, P2 receptors, transient 
receptor potential [TRP] channels), peptide receptor antago-
nists, nerve growth factor (NGF), and glial cell modulators. 
This review describes recent developments in the discovery of 
CB2 agonists, TRP vanilloid-1 (TRPV1) channel antagonists, 
P2 receptor   antagonists, and agents that target activated glia.
The CB receptors
The CB receptors are part of the endocannabinoid system 
and are G-protein coupled receptors. Their role in the 
  modulation of pain and inflammation is well documented.20–22 
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Figure 1 Summary of pain pathophysiology and some pain targets.
Abbreviations:  CB,  cannabinoid;  COX,  cyclooxygenase;  NMDA,  N-Methyl- 
D-aspartate.
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Figure 2 Chemical structures of some nonselective CB receptor modulators.
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Figure 3 Chemical structures of some selective CB2 receptor modulators.
Abbreviations: CB, cannabinoid; Ki, inhibition constant.
  Mammalian tissues express two types of CB receptors: 
CB1 and CB2 respectively. CB1 receptors are primarily 
expressed in the CNS, whereas CB2 receptors are primarily 
located in the periphery such as immune cells, spleen, and 
tonsils.23 In this regard, a number of CB receptor agonists 
were reported. The classic CBs, tetrahydrocannabinol 
(∆9-THC, Marinol®, Solvay Pharmaceuticals, Ixelles, Brus-
sels, Belgium)   (Figure 2, compound (1)) and dimethylheptyl 
tetrahydrocannabinol (HU-210) (Figure 2, compound (2)) 
based on a tricyclic terpenoid template are nonselective CB 
agonists with HU-210 exhibiting a greater degree of  binding 
affinity toward CB receptors (Figure 2). The major drawback 
of classical CB therapy in pain management is the impair-
ment of cognitive/motor function and altered psychological 
state.24,25 Compound CP-55,940 (Figure 2, compound (3)), 
a nonclassical CB was developed based on the chemical 
structure of ∆9-THC and played a major role in the discovery 
of the CB1 receptor.26 Consequently, the development of an 
aminoalkyl indole-based small molecule such as WIN55212 
(Figure 2, compound (4)) provided some degree of CB2 
selectivity.27 Eicosanoids such as anandamide22,28 represent 
endogenous CBs that exhibit greater affinity toward CB1 than 
CB2. Since centrally acting CB1 receptor agonists are known 
to produce CNS side effects such as dizziness and cognitive 
impairment, current focus is to develop CB2 receptor agonists 
that could produce minimal CNS side effects and to target 
CB1 receptors at the periphery.22,29,30
A number of small-molecule CB2 receptor agonists 
have been developed in the past decade as potential agents 
to treat nociceptive, inflammatory, and neuropathic pain. 
The mechanism of CB2-mediated analgesia is not clearly 
understood. Some studies suggest that CB2 agonists could 
act on immune cells and prevent the associated inflammatory 
response. A recent investigation by Hsieh and coworkers 
shows that the dorsal root ganglia and spinal cord regions are 
the potential sites of CB2-receptor-mediated analgesia.31 In 
this regard, one of the early CB2-receptor agonists HU-308 
(Figure 3, compound (5), a bicyclic derivative) exhibited 
high CB2 selectivity (CB2 inhibition constant [Ki] = 23 nM) 
and significant pain relief in the formalin model.32
A wide range of small molecules with diverse ring 
templates have been developed as CB2-selective agonists 
(Figures 3, 4, and 5). In this regard, several aminoalkyl indole-
based derivatives exhibit superior CB2 receptor binding and 
selectivity.33–36 For example, AM1241   (Figure 3, compound 
(6)) is a highly selective CB2-agonist (CB2 Ki = 3.4 nM; CB1 
Ki = 280 nM) that exhibits in vivo peripheral   analgesia in 
inflammatory and neuropathic pain models   without   exhibiting 
CNS side effects. Furthermore, the   aminoalkyl indole 
 ( Figure 3, compound (7)) was a highly selective CB2 receptor 
agonist (CB2 Ki = 1.9 nM; CB1 Ki . 10,000 nM; CB1/CB2 
selectivity . 5263). In another study, Cheng and coworkers 
developed a novel series of N-arylamide oxadiazoles where 
they identified an amide-linked quinolone derivative   (Figure 4, 
compound (8)) as a potent and selective CB2 agonist (CB2 
half-maximal effective concentration [EC50] = 2.2 nM) with 
excellent oral bioavailability profile in rats.37 In an   elegant 
study, a research team from   GlaxoSmithKline   discovered 
compound GW842166X (Figure 4, compound (9)) based on 
a   pyrimidinecarboxamide template as a clinical   candidate 
to treat   inflammatory pain. Compound GW842166X 
was a selective CB2 receptor agonist (CB2 EC50 = 63 nM; 
CB1EC50 . 30 µM) and exhibited potent oral activity (ED50 
[half-maximal effective dose] = 0.1 mg/kg) in animal models Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
282
Rao and Mohamed
H
N
N
H
N
H
N
H Cl
Cl
F
O
N
Cl
CF3
Cl
O
N
N
H
Me
O
Cl
(8) EC50 = 560 nM (CB1); 2.2 nM (CB2)
(10) EC50 = 6300 nM (CB1); 5 nM (CB2) (11) Ki = 592 nM (CB1); 4.0 nM (CB2)
(9) EC50 > 30 µM (CB1); 63 nM (CB2)
N
N
O
OO
N
N
N
C5H11
N
N
Figure 4 Chemical structures of some selective CB2 receptor modulators.
Abbreviations: CB, cannabinoid; EC50, half-maximal effective concentration; Ki, inhibition constant.
of inflammatory pain. Further lead   optimization provided 
the 5-azaindole (Figure 4, compound (10)) with superior 
CB2 binding affinity (CB2EC50 = 5 nM) and efficacy in both 
acute and chronic pain models.38,39 Another study showed that 
4-oxo-1,4-dihydropyridines could serve as useful templates 
to develop selective CB2 receptor ligands. The phenyl-sub-
stituted dihydropyridine (Figure 4, compound (11)) exhibited 
excellent CB2-binding affinity and was an inverse agonist 
(CB2 Ki = 4.0 nM; CB1 Ki = 592 nM).40 Rapid progress has 
been made in the development of CB2-selective ligands based 
on a wide variety of ring templates, and a detailed discussion 
is beyond the scope of this review.30 The evidence acquired 
to date, clearly supports targeting CB2, CB1/CB2, or CB1 
receptors and to develop “peripherally restricted” CB (CB2 
selective, dual CB1/CB2) agonists that exhibit reduced CNS 
side effects as novel agents in the pharmacotherapy of pain 
disorders.
The   TRP channels
The TRP channel family belongs to ligand-gated and voltage-
dependent ion channels/nociceptors that respond to chemical, 
mechanical, or thermal noxious stimuli at the periphery. They 
are divided into subfamilies. Many are located in the central 
and peripheral sensory neurons and are potential targets to 
treat neuropathic pain.41–43 The TRPV1 channels have been 
studied extensively and are known to play a critical role 
in peripheral sensitization of nociceptors and reduce pain 
threshold when activated by noxious stimuli. Its expression 
level is high in sensory neurons. The active ingredient of chili 
peppers, capsaicin (Figure 5, compound (12)) is a known 
activator of TRPV1 and is effective as a topical agent to treat 
pain states. Although opioids are used to treat chronic pain, 
they exhibit serious side effects such as dizziness, sedation, 
loss of cognitive function, dependency, respiratory depres-
sion, development of tolerance, and constipation. These 
shortcomings support the need to target novel pathways of 
pain. In this regard, the role of TRPV1 in peripheral sensi-
tization contributing to acute and chronic pain dictates the 
need to develop TRPV1 antagonists as potential agents to 
treat inflammatory and neuropathic pain.44–47 One of the early 
TRPV1 antagonists to enter the clinical trial was SB-705498 
(Figure 5, compound (13)) based on a pyrrolidine urea 
that exhibited excellent oral activity in animal models.48 
Furthermore, Amgen reported the discovery of a clinical 
candidate AMG517 (Figure 5, compound (14)) based on a 
oxopyrimidine ring template. Compound AMG517 exhib-
ited excellent TRPV1 inhibition (half-maximal inhibitory 
concentration [IC50] = 0.9 nM); however, it had a long half-
life and low aqueous solubility. Further lead optimization 
provided compound AMG628 (Figure, compound (15)), 
the piperazinylpyrimidine derivative that exhibited good 
TRPV1 inhibition, in vivo half-life, and aqueous solubility 
and was considered as a clinical candidate.49,50 Recently, 
Abbott Laboratories reported the discovery of an orally 
active clinical candidate (R)-1-(5-tert-butyl-2,3-dihydro-1-
H-inden-1-yl)-3-(1H-indazol-4-yl) urea (ABT102, Figure 5, 
compound (16)) to treat chronic pain. This small molecule 
exhibited potent TRPV1 binding (TRPV1 IC50 = 4 nM) and Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Figure 5 Chemical structures of some TRPV1 receptor antagonists.
Abbreviations:  EC50,  half-maximal  effective  concentration;  IC50,  half-maximal 
inhibitory concentration; TRPV1, transient receptor potential vanilloid-1.
was effective in various in vivo pain models such as carra-
geenan induced postoperative and cancer pain. In addition, 
this agent did not exhibit side effects such as sedation and 
constipation commonly seen with opiate therapy, highlight-
ing the fact that selective targeting of  TRPV1 should provide 
agents that lack the adverse side effects of opiates.51–53 
Accordingly, several small-molecule candidates are being 
developed by the pharmaceutical companies.41,47,54 The rep-
resentative examples discussed here indicate the enormous 
potential of targeting TRPV1 receptors to treat both acute 
and chronic pain. Compared with peripherally restricted CB 
agonists, TRPV1 receptor modulators reduce pain by acting 
on both central and peripheral pain pathways, suggesting 
their potential to cause CNS side effects. The challenges 
include recognizing TRPV1 gene polymorphism in patients 
to predict desired therapeutic responses and identify potential 
side effects such as hyperthermia.46
P2X receptors
The neurotransmitter ATP (adenosine-5′-triphosphate) is 
known to produce pain through activating the purinergic 
receptors P1 and P2. The P1 receptors are known as adenosine 
receptors, whereas P2 receptors are further divided into P2Y 
(G-protein coupled receptors) and P2X (ligand-gated chan-
nels). The P2X receptors are subdivided into seven receptor 
subtypes (P2X1, P2X2, P2X3, P2X4, P2X5, P2X6, and 
P2X7 respectively) and have attracted widespread attention 
as potential targets to develop novel pain therapeutics.55–58 
Among the P2X family, P2X7 is known to be present in 
immune cells such as monocytes, macrophages, mast cells, 
lymphocytes, and microglia, indicating their role in disor-
ders such as pain, neurodegeneration, and inflammatory 
conditions.59,60 In this regard, novel P2X7 receptor antagonists 
are being developed as clinical candidates to treat acute and 
chronic pain.61 Scientists at Abbott Laboratories reported the 
development of some distinct small molecules as P2X7 recep-
tor antagonists. In this regard, the 1-benzyl-5-phenyltetrazoles 
(Figure 6, compound (17)) exhibited potent P2X7 inhibition 
and were effective in a neuropathic pain model. In another 
study, a series of N´-acyl hydrazides was reported as a novel 
series of P2X7 receptor antagonists with in vivo activity. 
Compound (18) shown in Figure 6 was identified as a potent 
P2X7 receptor antagonist. Further studies led to the devel-
opment of a novel series of cyanoguanidines with potent 
P2X7 inhibition, and compound (19) (Figure 6) was effective 
in a neuropathic pain model.62–64 In addition, researchers from 
AstraZeneca reported the development of adamantine-based 
small molecules (eg, compound (20) shown in Figure 6) as 
P2X7 receptor antagonists with ability to prevent the forma-
tion of the pro-inflammatory cytokine interleukin-1β.65 A 
detailed description of several small-molecule P2X   receptor 
modulators has been reviewed elsewhere.61,66
Targeting glia cells
Recent studies have focused on the role of non-neuronal 
cells such as astrocytes and glia or glial cells in pain 
  pathophysiology. Under pathological conditions, glial cells Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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get activated and are known to release pro-inflammatory 
cytokines, chemokines, and other signaling molecules that 
contribute to neuropathic pain.67–69 Some strategies include 
blocking glial cell activation, prevent the biosynthesis of pro-
inflammatory cytokines, block the action of pro-inflammatory 
cytokines, and disrupt their signaling. In this regard, the tetra-
cycline antibiotic minocycline (Figure 7, compound (21)) is 
known to selectively target microglia and could suppress the 
release of pro-inflammatory cytokines, whereas the xanthine 
  derivative pentoxyfylline (Trental®, Aventis, Strasbourg, 
France)   (Figure 7, compound (22)) currently used to treat 
chronic occlusive arterial disease and AV411 (KetasTM, Senju 
Pharmaceutical Co, Osaka, Japan)   are known to inhibit pro-
  inflammatory cytokine biosynthesis. These small molecules are 
able to cross the blood–brain barrier, indicating their potential 
to target neuropathic pain. In contrast, biological molecules 
such as etanercept (Enbrel®, Amgen, Thousand Oaks, CA) 
and the interleukin-1β antagonist anakinra (Kineret®, Amgen) 
are known to exhibit efficacy in neuropathic animal models, 
suggesting their ability to block glial cell mediated cytokine 
signaling.68 However, these agents are injectables that exhibit 
poor CNS penetration. In the last decade, glial cells have 
emerged as attractive targets to prevent chronic pain.70,71 In this 
regard, the neuroprotective nature of glial cells during tissue 
injury suggests a careful approach toward developing novel 
glial cell modulators. The molecular mechanisms of glial cell 
activation and its consequences is still a work in progress.
Conclusion
The last decade has seen an unprecedented surge in under-
standing the complexity of pain pathology. The identifica-
tion of novel pain targets such as CB receptors, FAAH, 
voltage- and ligand-gated ion channels (sodium channels, 
T-type calcium channels, P2X receptors, TRP channels), 
peptide receptor antagonists, NGF and glial cell modulators 
to treat nociceptive, inflammatory, and neuropathic pain is 
highly promising. Preclinical data shows that one can develop 
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peripherally restricted agents such as CB receptor   modulators 
and FAAH inhibitors that do not exhibit psychotropic effects 
indicating their superior side-effect profile compared with 
traditional pain therapies. The challenge is to prove the effi-
cacy seen in preclinical data of novel agents with clinical 
evidence. The benefit-to-risk ratios of novel pain therapies 
will come under careful scrutiny of regulatory agencies. 
Despite the challenges ahead, it is clear that understanding 
the molecular mechanisms of novel pain targets will go a 
long way in developing selective or “site specific” agents 
that exhibit efficacy and superior side-effect profile as pain 
therapeutics.
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